Nicole Kieffer, DO
Rheumatology · Green Bay, WINPI 1689854853
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 46.0% of the total.
Across 70 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$544
- Amgen$240
- GSK$207
- UCB, Inc.$58
- Johnson & Johnson$28
- Octapharma USA, Inc.$23
- plus $81 from 5 others
What the payments were for
- Food & beverage$1,177100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $544 |
| Amgen | 14 | $240 |
| GSK | 11 | $207 |
| UCB, Inc. | 2 | $58 |
| Johnson & Johnson | 2 | $28 |
| Octapharma USA, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Organon | 2 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$1,183 in reported general payments places this provider in the 60th percentile of 120 rheumatology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 18 | $125,507 |
| Xeljanz XrTofacitinib Citrate | 11 | $60,315 |
| Hydroxychloroquine Sulfate | 66 | $2,903 |
| Colchicine | 23 | $2,704 |
| MethotrexateMethotrexate Sodium | 116 | $1,644 |
| Prednisone | 122 | $1,016 |
| Sulfasalazine | 22 | $610 |
| Allopurinol | 39 | $404 |
| Alendronate Sodium | 32 | $324 |
| Folic Acid | 44 | $269 |
| Meloxicam | 11 | $72 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Green Bay
- Isabelle AmiguesGreen Bay$80K
- Marlon HermitanioGreen Bay$4K
- Paul UtrieGreen Bay$4K
- Paul TuttleGreen Bay$4K
- Debbie LimGreen Bay$4K
- Karim DoughemGreen Bay$2K
- Michael AveryGreen Bay$2K
- Ardy FenandoGreen Bay$2K
- Lauren BerryGreen Bay$2K
- Dana TrotterGreen Bay$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.